Cutolo M, Cimmino MA, Perez-Ruiz F. Potency on lowering serum uric acid in gout patients: a pooled analysis of registrative studies comparing febuxostat vs allopurinol. Eur Rev Med Pharmacol Sci.2017;21:4186-4195. PMID: 29028079
Borghi C et al. Serum uric acid and the risk of cardiovascular and renal disease. J Hypertens 2015;33:1729-1741. doi: 10.1097/HJH.0000000000000701.
Mancia G, Grassi G, Broghi C. Hyperuricemia, urate deposition and the association with hypertension. Curr Med Res Opin 2015: 31: 15-19. doi: 10.1185/03007995.2015.1087981.
Richete P et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis 2017; 76: 29-42. doi: 10.1136/annrheumdis-2016-209707. Epub 2016 Jul 25
Khanna D et al. American College of Rheumatology 2012 Guidelines for Management of Gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arhtritis Care Res (Hoboken) 2012; 64: 1431-1446. doi: 10.1002/acr.21772
Gerriets V, Jialal I. Febuxostat. Treasure Island (FL): StatPearls Publishing; 2021 Jan-. https://www.ncbi.nlm.nih.gov/books/NBK544239/
Faruque LI, Ehteshami-Afshar A, Wiebe N, Tjosvold L, Homik J, Tonelli M. A systematic review and meta-analysis on the safety and efficacy of febuxostat versus allopurinol in chronic gout. Semin Arthritis Rheum. 2013;43(3):367-375. doi:10.1016/j.semarthrit.2013.05.004
Li, S., Yang, H., Guo, Y. et al. Comparative efficacy and safety of urate-lowering therapy for the treatment of hyperuricemia: a systematic review and network meta-analysis. Sci Rep 6, 33082 (2016). https://doi.org/10.1038/srep33082
Mackenzie IS et al. FASR Study Group. Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, ope label, non-inferiority trial. Lancet.2020;396(10264):1745-1757. doi: 10.1016/S0140-6736(20)32234-0.
Gao, L, Wang, B, Pan, Y, Lu, Y, Cheng, R. Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: A systematic and meta-analysis. Clin Cardiol. 2021; 44( 7): 907– 916.https://doi.org/10.1002/clc.23643
Rey, A., Batteux, B., Laville, S.M. et al. Acute kidney injury associated with febuxostat and allopurinol: a post-marketing study. Arthritis Res Ther 21, 229 (2019). https://doi.org/10.1186/s13075-019-2011-y
Yang AY. Comparison of long-term efficacy and renal safety of febuxostat and allopurinol in patients with chronic kidney diseases
. Int J Clin Pharmacol Ther. 2020;58(1):21-28. doi:10.5414/CP203466
Peng, YL., Tain, YL., Lee, CT. et al. Comparison of uric acid reduction and renal outcomes of febuxostat vs allopurinol in patients with chronic kidney disease. Sci Rep 10, 10734 (2020). https://doi.org/10.1038/s41598-020-67026-1